-+ 0.00%
-+ 0.00%
-+ 0.00%

Avalo Therapeutics FY2025 net loss widens 123% to USD 78 million, R&D expenses rise 105% to USD 50 million

Reuters·03/23/2026 11:01:36

Please log in to view news